業務分野

薬事関連規制・バイオテクノロジー規制法

当事務所主催イベント

Going Global 2018

法域およびプラクティス横断のグローバルセミナー

クイックビュー 全文を見る

ニュースレター等

[Pharmaceutical and Biotechnology Alert] FDA Takes Steps to Clarify Significant Human Tissue Questions Medical Device, Pharmaceutical, and Biotechnology Alert

On October 30, 2015, the Food and Drug Administration (FDA) issued a draft guidance document, Homologous Use of Human Cells, Tissues, and Cellular and Tissue-Based Products (the Homologous...

クイックビュー 全文を見る

ニュースレター等

[Medical Device Alert] Important New Steps in the Evolution of the Federal Policy for Protection of Human Subjects Pharmaceutical and Biotechnology and Medical Device Alert

On September 2, 2015, the U.S. Department of Health and Human Services (HHS) and 15 other federal agencies issued a long-anticipated Notice of Proposed Rulemaking (NPRM) to overhaul...

クイックビュー 全文を見る

ニュースレター等

[Health Alert] 340B Program: HRSA Releases Proposed “Omnibus” or “Mega” Guidance, Which Lives Up To Its Name Health, Pharmaceutical, and Biotechnology Alert

The Health Resources and Services Administration (HRSA) yesterday released its “340B Drug Pricing Program Omnibus Guidance,” also known as the “Mega-Guidance,” in proposed form.

クイックビュー 全文を見る

ニュースレター等

[Pharmaceutical and Biotechnology Alert] May the Truth Set You Free: Amarin Prevails In Its First Amendment Case Against FDA Pharmaceutical and Biotechnology Alert

On August 7, 2015, the U.S. District Court for the Southern District of New York ruled in favor of Amarin Pharma, Inc. (Amarin) in its suit against the U.S. Food and Drug Administration...

クイックビュー 全文を見る

ニュースレター等

[Health Alert] 340B Program: HRSA Releases Proposed Rule on Calculation of the Ceiling Price and Imposition of Civil Monetary Penalties on Manufacturers Health, Pharmaceutical, and Biotechnology Alert

Today, the Health Resources and Services Administration (HRSA) released a Notice of Proposed Rulemaking (NPRM) regarding the calculation of the 340B ceiling price and the imposition of...

クイックビュー 全文を見る
Loading data